[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"epro\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:epro":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100656732","impact-of-routine-electronic-patient-reported-outcome-eprosymptom-monitoring-during-neoadjuvant-therapy-in-patients-withpancreatic-adenocarcinoma-on-patient-experience-and-clinicaloutcomes-a-prospective-pre-post-implementation-study-100656732",false,"NCT07829471","Impact of Routine Electronic Patient-Reported Outcome (ePRO)Symptom Monitoring During Neoadjuvant Therapy in Patients withPancreatic Adenocarcinoma on Patient Experience and ClinicalOutcomes: A Prospective Pre-Post Implementation Study","Eligibility Criteria\n\n* Age ≥18 years\n* Participants must have histologically confirmed PDAC that is respectable, borderline respectable, or locally advanced with potential for curative intent resection as defined by MD Anderson Cancer Center (Appendix V)\n* Participants must be eligible to receive systemic neoadjuvant therapy (chemotherapy +\u002F- radiation therapy) with intent for curative resection\n* Participants who will receive neoadjuvant therapy at an MD Anderson facility including Texas Medical Center and Houston area locations\n* Participants must be able to understand English or Spanish\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria\n\n* Definitively unresectable or metastatic disease at enrollment\n* Participants who received pre-referral chemotherapy, chemoradiotherapy, or previously attempted resection\n* Participants who had prior curative intent surgery for pancreatic cancer before entering the study\n* Participant with cognitive deficits that would preclude understanding of consent form and\u002For questionnaires\n* Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Participants who do not understand English or Spanish\n* Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia\n* Participants with uncontrolled underlying medical conditions\n* Participants receiving chemotherapy outside of the MD Anderson system","ALL","18 Years",{"count":18,"type":19},200,"ESTIMATED","INTERVENTIONAL",[22],"NA","To learn if routine symptom monitoring using questionnaires during chemotherapy and\u002For radiation therapy in patients with PDAC improves patient health-related quality of life and experience with care.",[25,26,27,28,29],"ePRO","Symptom Monitoring","Neoadjuvant Therapy","Pancreatic Adenocarcinoma","Clinical Outcomes","NOT_YET_RECRUITING","2026-09-17",{"date":33,"type":34},"2026-09-21","ACTUAL",{"date":36,"type":19},"2027-02-21",{"date":38,"type":19},"2032-07-01",{"name":40,"class":41},"M.D. Anderson Cancer Center","OTHER"]